Allogene Therapeutics Inc. reported a net loss of $59.7 million for the first quarter of 2025, translating to a loss of $0.28 per share. The results include a non-cash stock-based compensation expense of $12.2 million. As of March 31, 2025, the company held $335.5 million in cash, cash equivalents, and investments. In light of the evolving macroeconomic environment, Allogene has implemented strategic cost-realignment efforts to optimize operations and extend its financial runway. These measures prioritize high-impact, value-generating programs such as the clinical advancement of cema-cel in the ALPHA3 trial and ALLO-329 in the RESOLUTION trial. Operational savings have been achieved through tactical reductions in manufacturing operations, leveraging existing infrastructure investments and efficiencies from the company's allogeneic CAR T platform. These actions have extended the cash runway into the second half of 2027. New guidance for 2025 anticipates a decrease in cash, cash equivalents, and investments by approximately $150 million. GAAP operating expenses for the year are expected to be around $230 million, with an estimated non-cash stock-based compensation expense of approximately $45 million. This excludes any potential impact from business development activities.